Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
95,963,102
-
Total 13F shares
-
55,205,870
-
Share change
-
-787,132
-
Total reported value
-
$2,358,324,671
-
Put/Call ratio
-
666%
-
Price per share
-
$42.71
-
Number of holders
-
160
-
Value change
-
-$33,639,501
-
Number of buys
-
88
-
Number of sells
-
67
Institutional Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q4 2019
As of 31 Dec 2019,
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) was held by
160 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
55,205,870 shares.
The largest 10 holders included
Capital Research Global Investors, Capital International Investors, VANGUARD GROUP INC, BlackRock Inc., PRICE T ROWE ASSOCIATES INC /MD/, Capital World Investors, STATE STREET CORP, FMR LLC, ALLIANCEBERNSTEIN L.P., and CITADEL ADVISORS LLC.
This page lists
161
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.